AbCellera’s second COVID-19 antibody treatment enters clinical trial


The Vancouver-based biotech said its partnership with U.S. pharmaceutical giant Eli Lilly has yielded a second antibody, LY-CoV1404, that has entered ongoing clinical trials. The company said preclinical, pre-peer-review data shows it “neutralizes all currently known variants of concern” including those first identified in the U.K., South Africa, Brazil, California and New York. (The Logic)

Read this article for free

By entering your e-mail you consent to receiving commercial electronic messages from The Logic Inc. containing news, updates, offers or promotions about The Logic Inc.’s products and services. You can withdraw your consent at anytime. Please refer to our privacy policy or contact us for more details.

Already a subscriber?